Recombinant Anti-CD16 x Anti-GD2 Bispecific Antibody (scFv-Fc) (BSCFV-037)

Recombinant Anti-CD16 x Anti-GD2 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CD16 specificity or anti-GD2 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can retarget NK cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD16 & GD2

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors

Targets

Target 1

CD16

Gene ID

2214

UniProt ID

M9MML0

Alternative Names

FCGR3A; Fc fragment of IgG, low affinity IIIa, receptor (CD16a); CD16; FCG3; CD16A; FCGR3; IGFR3; IMD20; FCR-10; FCRIII; FCGRIII; FCRIIIA; low affinity immunoglobulin gamma Fc region receptor III-A; FcγRIII; FcgammaRIIIA; CD16a antigen; fc-gamma RIII; Fc-gamma RIIIa; Fc-gamma RIII-alpha; igG Fc receptor III-2; Fc gamma receptor III-A; Fc-gamma receptor IIIb (CD16); neutrophil-specific antigen NA; Fc-gamma receptor III-2 (CD 16); immunoglobulin G Fc receptor III; Fc fragment of IgG, low affinity III, receptor for (CD16)

Target 2

GD2

Alternative Names

Ganglioside GD2; GD2; Ganglioside; Disialoganglioside GD2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD16 x Anti-GD2 Bispecific Antibody (scFv-Fc) (BSCFV-037). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD16 x Anti-GD2 Bispecific Antibody (scFv-Fc) (CAT#: BSCFV-037)

Specifications

Targets

Customer Reviews and Q&As